RXRX RECURSION PHARMACEUTICALS, INC.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.

$33.19  +1.96 (6.26%)
As of 06/14/2021 15:59:20 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Unknown
Industry:  
Index country:  USA
Country of incorporation:  
IPO date:  12/18/2002
Outstanding shares:  168,320,745
Average volume:  309,547
Market cap:   $5,088,336,121
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    75629V104
ISIN:        
Sedol:      
Valuation   (See tab for details)
PE ratio:   -106.97
PB ratio:   -22.56
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy